BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 34449814)

  • 1. Health-related quality of life using EQ-5D among chronic myeloid leukaemia patients in health centres in Klang Valley, Malaysia.
    Wan Puteh SE; Aizuddin AN; Tumian NR; Sathar J; Mohamad Selamat E
    PLoS One; 2021; 16(8):e0256804. PubMed ID: 34449814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure.
    Whiteley J; Reisman A; Shapiro M; Cortes J; Cella D
    Curr Med Res Opin; 2016 Aug; 32(8):1325-34. PubMed ID: 27045164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inequality in Drug Utilization among Chronic Myeloid Leukaemia Patients in Malaysia: A Cost-Utility Analysis.
    Wan Puteh SE; Mohamad Selamat E; Aizuddin AN; Tumian NR; Sathar J
    Asian Pac J Cancer Prev; 2022 Dec; 23(12):4253-4260. PubMed ID: 36580008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A survey on tyrosine kinase inhibitor treatment in patients with chronic myeloid leukemia in China: from patients'perspective].
    Jiang Q; Liu ZC; Zhang SX
    Zhonghua Xue Ye Xue Za Zhi; 2016 Jul; 37(7):559-64. PubMed ID: 27535854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment status of tyrosine kinase inhibitors in Chinese patients with chronic myeloid leukemia in 2020].
    Wang HF; Zhang YL; Liu XL; Zhu HL; Liang R; Liu BC; Zhou L; Meng L; Li WM; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2021 Jul; 42(7):535-542. PubMed ID: 34455739
    [No Abstract]   [Full Text] [Related]  

  • 6. [Comorbidity profile and its impact on reported outcome in Chinese patients with chronic myeloid leukemia in chronic phase receiving tyrosine kinase-inhibitor therapy].
    Yu L; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2018 Jul; 39(7):533-539. PubMed ID: 30122010
    [No Abstract]   [Full Text] [Related]  

  • 7. Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient's perspective.
    Hirji I; Gupta S; Goren A; Chirovsky DR; Moadel AB; Olavarria E; Victor TW; Davis CC
    Health Qual Life Outcomes; 2013 Oct; 11():167. PubMed ID: 24099272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years.
    Lang AS; Mounier M; Roques M; Chretien ML; Boulin M
    J Clin Pharm Ther; 2015 Aug; 40(4):391-7. PubMed ID: 25865674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive Evaluation of Adherence to Therapy, Its Associations, and Its Implications in Patients With Chronic Myeloid Leukemia Receiving Imatinib.
    Unnikrishnan R; Veeraiah S; Mani S; Rajendranath R; Rajaraman S; Vidhubala Elangovan GS; Radhakrishnan V; Ganesan TS; Sagar TG; Ganesan P
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):366-371.e3. PubMed ID: 27052853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy.
    Jiang Q; Wang HB; Yu L; Gale RP
    J Cancer Res Clin Oncol; 2017 Jun; 143(6):1013-1022. PubMed ID: 28251350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real world treatment patterns in chronic myeloid leukemia patients newly initiated on tyrosine kinase inhibitors in an U.S. integrated healthcare system.
    Rashid N; Koh HA; Lin KJ; Stwalley B; Felber E
    J Oncol Pharm Pract; 2018 Jun; 24(4):253-263. PubMed ID: 29284347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Patient reported outcome of tyrosine kinase inhibitor related side effects and their impact on daily life in Chinese patients with chronic myeloid leukemia in the chronic phase].
    Yu L; Wang HB; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2016 Nov; 37(11):929-935. PubMed ID: 27995875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy.
    Efficace F; Stagno F; Iurlo A; Breccia M; Cottone F; Bonifacio M; Abruzzese E; Castagnetti F; Caocci G; Crugnola M; Capodanno I; Martino B; Tiribelli M; Patriarca A; Gozzini A; Pregno P; Saussele S; Cascavilla N; Fozza C; Bergamaschi M; Binotto G; Vignetti M; Rosti G
    Leukemia; 2020 Feb; 34(2):488-498. PubMed ID: 31477798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing health-related quality of life in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
    Efficace F; Vignetti M; Sparano F; Scalzulli E; Breccia M
    Expert Rev Hematol; 2021 Mar; 14(3):293-302. PubMed ID: 33554672
    [No Abstract]   [Full Text] [Related]  

  • 15. Prevalence of BCR-ABL T315I Mutation in Malaysian Patients with Imatinib-Resistant Chronic Myeloid Leukemia.
    Mat Yusoff Y; Abu Seman Z; Othman N; Kamaluddin NR; Esa E; Zulkiply NA; Abdullah J; Zakaria Z
    Asian Pac J Cancer Prev; 2018 Dec; 19(12):3317-3320. PubMed ID: 30583336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generic imatinib in the treatment of chronic myeloid leukemia: two years' experience in Latvia.
    Lejniece S; Udre I; Rivkina A
    Exp Oncol; 2017 Jul; 39(2):151-154. PubMed ID: 29483494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship.
    Koller PB; Kantarjian HM; Nogueras-Gonzalez GM; Jabbour E; Verstovsek S; Borthakur G; Estrov Z; Wierda WG; Garcia-Manero G; Ferrajoli A; Ravandi F; O'Brien SM; Cortes JE
    Cancer; 2017 Feb; 123(4):609-616. PubMed ID: 27763690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of new generic formulations of imatinib mesylate on general quality of life in chronic phase chronic myeloid leukaemia patients.
    Uyanik MS; Pamuk GE; Maden M; Merev E; Cevik G; Uyanik V; Umit EG; Demir AM; Akker M
    Eur J Cancer Care (Engl); 2017 Mar; 26(2):. PubMed ID: 26594025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.
    Faye BF; Dieng N; Seck M; Gadji M; Gueye YB; Sy D; Toure SA; Sall A; Toure AO; Dieye TN; Diop S
    Ann Hematol; 2016 Oct; 95(10):1603-10. PubMed ID: 27370991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population.
    Efficace F; Baccarani M; Breccia M; Alimena G; Rosti G; Cottone F; Deliliers GL; Baratè C; Rossi AR; Fioritoni G; Luciano L; Turri D; Martino B; Di Raimondo F; Dabusti M; Bergamaschi M; Leoni P; Simula MP; Levato L; Ulisciani S; Veneri D; Sica S; Rambaldi A; Vignetti M; Mandelli F;
    Blood; 2011 Oct; 118(17):4554-60. PubMed ID: 21750313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.